Company: VERA
Filing Date: 2025-12-10
Form Type: 424B5
Source: 0001193125-25-314244
Chunk: 25

Company: Vera Therapeutics, Inc.
Filing Date: 2025-12-10
Form: 424B5
Chunk 25
---
 by the lock-up party or any family member; (iv) transfers of the lock-up securities by operation of law pursuant to a qualified
domestic order or other court order or in connection with a divorce settlement; (v) if the lock-up party is a corporation, partnership, limited liability company, trust or other business entity,

S-18

distributions or transfers of the lock-up securities to (x) another corporation, partnership, limited liability company, trust or other business
entity that is a direct or indirect affiliate (as defined in Rule 405 promulgated under the Securities Act) of the lock-up party, (y) any investment fund or other entity controlling, controlled by,
managing or managed by or under common control with the lock-up party or affiliates of the lock-up party (including, for the avoidance of doubt, where the lock-up party is a partnership, to its general partner or a successor partnership or fund, or any other funds managed by such partnership), or (z) limited partners, general partners, members, directors,
officers, employees, managers, managing members, stockholders or other equity holders of the lock-up party or of the entities described in the preceding clauses (x) and (y); (vi) transfers or dispositions
of common stock to us as forfeitures (x) to satisfy tax withholding and remittance obligations of the lock-up party in connection with the vesting or exercise of equity awards granted pursuant to our
equity incentive plans or (y) pursuant to a net exercise or cashless exercise by the stockholder of outstanding equity awards pursuant to our equity incentive plans; provided, however, that in each case, any such equity incentive plans exist as
of the date of the underwriting agreement and are described in this prospectus supplement; (vii) transfers of the lock-up securities pursuant to a change of control of the company (meaning the
consummation of any bona fide third party tender offer, merger, consolidation or other similar transaction made to all holders of common stock the result of which is that any “person” (as defined in Section 13(d)(3) of
the Exchange Act), or group of persons other than the company or its subsidiaries, becomes the beneficial owner (as defined in Rules 13d-3 and 13d-5 of the Exchange
Act) of more than 50% of the voting capital stock of the company) after this offering that has been approved by the independent members of our board of directors,